openPR Logo
Press release

Enzyme Inhibitor Market Report 2024: Strategies And Recent Developments | Abbott Laboratories, Amgen Inc., AstraZeneca plc, Bayer AG, F. Hoffmann-La Roche AG, Pfizer Inc

Enzyme Inhibitor  Market Size

Enzyme Inhibitor Market Size

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2279

The Business Research Company offers in-depth market insights through Enzyme Inhibitor Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The enzyme inhibitor market size has grown steadily in recent years. It will grow from $180.38 billion in 2023 to $186.04 billion in 2024 at a compound annual growth rate (CAGR) of 3.1%. The growth in the historic period can be attributed to increased demand for enzyme inhibitors in the treatment of various diseases, advancements in drug discovery and development, growing prevalence of chronic diseases, increased geriatric population, rising awareness about the benefits of enzyme inhibitors.

The enzyme inhibitor market size is expected to see steady growth in the next few years. It will grow to $216.75 billion in 2028 at a compound annual growth rate (CAGR) of 3.9%. The growth in the forecast period can be attributed to growing investment in research and development activities, increasing demand for personalized medicine, rising incidence of chronic diseases in emerging markets, growing demand for enzyme inhibitors in the treatment of cancer, expansion of applications in rare and genetic diseases. Major trends in the forecast period include development of reversible and irreversible enzyme inhibitors, exploration of natural products as sources of enzyme inhibitors, integration of computational methods in enzyme inhibitor discovery, emphasis on personalized dosing and treatment regimens, expansion of enzyme inhibitor applications in oncology and neurodegenerative diseases..

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=6728&type=smp

Market Segmentation:
The enzyme inhibitor market covered in this report is segmented -

1) By Type: Proton Pump Inhibitors (PPIs), Protease Inhibitors, Reverse Transcriptase Inhibitors, Aromatase Inhibitors, Kinase Inhibitors, Neuraminidase Inhibitors, Statins, Other Types
2) By Disease Indication: Chronic Obstructive Pulmonary Disorders, Cardiovascular Disease, Gastrointestinal Disorders, Arthritis, Inflammatory Diseases, Other Disease Indications
3) By Application: Chemotherapy, Antibiotics, Pesticides, Cardiovascular Treatments, Other Applications
4) By End User: Pharmaceutical, Biotechnology, Food and Beverage, Other End Users

Major Driver - Driving Forces Behind Enzyme Inhibitor Market Growth Impact Of Disease Incidence, Cancer Statistics, And Therapeutic Advancements
The rise in the incidence of diseases including cancer is expected to propel the growth of the enzyme inhibitor market going forward. Enzymes, such as telomerase, which is active in most tumor cells, are utilized to cure cancers, including leukemia, and also keep healthy adult cells from becoming cancerous. For instance, in January 2022, according to the American Cancer Society, a US-based non-profit healthcare group dedicated to cancer elimination, on average in the US, 1,670 individuals are going to die from cancer every day in 2022, with 1.9 million cases being diagnosed and 609,360 fatalities. Therefore, the rise in the incidence of diseases such as cancer is driving the demand for the enzyme inhibitor market growth.

Competitive Landscape:
Major companies operating in the enzyme inhibitor market report are Abbott Laboratories, Amgen Inc., AstraZeneca plc, Bayer AG, F. Hoffmann-La Roche AG, Pfizer Inc., Ranbaxy Laboratories Limited, Takeda Pharmaceutical Company, Merck and Co. Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Cipla USA Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals, Acellera Ltd., Bioinfogate SL, BioSolveIT GmbH, Dassault Systèmes BIOVIA Corp., ChemAxon Ltd., Cheminformatics Tools and Services LLC, Cresset BioMolecular Discovery Ltd., Dotmatics Limited, Enamine Ltd., Forge Therapeutics Inc., Inte:Ligand GmbH, LeadIT, Molecular Forecaster Inc., Chemical Computing Group Inc., OpenEye Scientific Software Inc.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/enzyme-inhibitor-global-market-report

Top Trend - Rising Trend Strategic Collaborations Driving Innovation And Market Expansion In The Enzyme Inhibitor Industry
Strategic partnerships and collaborations have emerged as a key trend gaining popularity in the enzyme inhibitor market. Major companies operating in enzyme inhibitors are focused on strategic partnerships to meet customer demand. For instance, in April 2021, Artios Pharma Limited, a UK-based DNA damage response company that also provides enzyme inhibitors, collaborated with Novartis International AG, a Switzerland-based pharmaceutical corporation, to uncover and verify new generation DDR (DNA Damage Response) targets to advance Novartis' Radioligand Therapies (RLT). This partnership with Novartis will be utilized to find and validate next-generation DDR targets to improve Novartis' radioligand therapies.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Enzyme Inhibitor Market Characteristics
3. Enzyme Inhibitor Market Trends And Strategies
4. Enzyme Inhibitor Market - Macro Economic Scenario
5. Enzyme Inhibitor Market Size And Growth
…..
27. Enzyme Inhibitor Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Enzyme Inhibitor Market Report 2024: Strategies And Recent Developments | Abbott Laboratories, Amgen Inc., AstraZeneca plc, Bayer AG, F. Hoffmann-La Roche AG, Pfizer Inc here

News-ID: 3416770 • Views:

More Releases from The Business Research Company

Wear Parts Market Size, Growth Analysis, Trends And Forecast 2033
Wear Parts Market Size, Growth Analysis, Trends And Forecast 2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033. Wear Parts Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance. The Market Size Is Expected To Reach $796.11 billion In 2028 At
Assured Positioning, Navigation, And Timing (PNT) Market Report 2024: Market Size And Growth Factors
Assured Positioning, Navigation, And Timing (PNT) Market Report 2024: Market Siz …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033. Assured Positioning, Navigation, And Timing (PNT) Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance. The Market Size Is Expected To Reach $2.94
Hope for Sickle Cell: Treatment Market Growth and Trends 2024-2033
Hope for Sickle Cell: Treatment Market Growth and Trends 2024-2033
The sickle cell disease treatment market size has grown rapidly in recent years. It will grow from $2.46 billion in 2023 to $2.95 billion in 2024 at a compound annual growth rate (CAGR) of 20.0%. The growth in the historic period can be attributed to disease understanding, blood transfusions, pain management, hydroxyurea therapy. The sickle cell disease treatment market size is expected to see rapid growth in the next
Easing the Pain: Neuropathic Pain Market Growth and Future Trends 2024-2033
Easing the Pain: Neuropathic Pain Market Growth and Future Trends 2024-2033
The neuropathic pain market size has grown strongly in recent years. It will grow from $4.95 billion in 2023 to $5.35 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to increasing demand for neuropathic pain drugs, chronic pain epidemic, growing demand for prescription treatments, government initiatives. The neuropathic pain market size is expected to see strong

All 5 Releases


More Releases for Inhibitor

Immune Checkpoint Inhibitor
Immune Checkpoint Inhibitors Market Insights 2019, Global and Chinese Scenario is a professional and indepth study on the current state of the global Immune Checkpoint Inhibitors industry with a focus on the Chinese market. The report provides key statistics on the market status of the Immune Checkpoint Inhibitors manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Overall, the report provides an
Galectin Inhibitor Therapeutics - Pipeline Analysis 2019
Galectins belong to the family of animal lectins and perform function by interacting with cytoplasmic and nuclear proteins, cell-surface and extracellular matrix glycoproteins and glycolipids to modulate signalling pathways. Studies have shown the crucial roles of galectin in cancer as they contribute to tumour cell survival, tumour metastasis, angiogenesis and neoplastic transformation. Download the sample Report @ https://www.pharmaproff.com/request-sample/1209 Many studies have demonstrated role of galectins in the pathogenesis of various diseases including
Galectin Inhibitor Therapeutics - Pipeline Analysis 2019
Galectins belong to the family of animal lectins and perform function by interacting with cytoplasmic and nuclear proteins, cell-surface and extracellular matrix glycoproteins and glycolipids to modulate signalling pathways. Studies have shown the crucial roles of galectin in cancer as they contribute to tumour cell survival, tumour metastasis, angiogenesis and neoplastic transformation. Download the sample Report @ https://www.pharmaproff.com/request-sample/1209 Many studies have demonstrated role of galectins in the pathogenesis of various diseases including
Neuroendocrine Carcinoma Market: Both tyrosine kinase inhibitor and mTOR inhibit …
Recently, Future Market Insights has presented value analysis and insights on the various disease types, treatment types and end users associated with the neuroendocrine carcinoma market across key regions in the globe. It has also included an in-depth analysis on the various key players participating in the global neuroendocrine carcinoma market along with key developments taking place during the 2017-2027 timeline. Future Market Insights, in its recent publication titled “Neuroendocrine
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor o …
"The Report Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Summary Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) pipeline Target constitutes close to 10 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The latest report
Cytokine Inhibitor Market Research Report 2017
Reports And Markets Publish a New Market Research Report On –"Cytokine Inhibitor Market Research Report 2017" Access Full Report With Table Of Contents @ https://www.reportsandmarkets.com/reports/global-cytokine-inhibitor-market-research-report-2017-1541209 In this report, the global Cytokine Inhibitor market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions,